Smith & Nephew plc research snapshot
SNN AI stock analysis currently reads Smith & Nephew plc as a global medical technology company that finished its 12-Point Plan with higher revenue, trading margin, and free cash flow, then moved into a RISE strategy aimed at faster growth and returns. At the July 8, 2026 data cutoff, SNN closed at $29.95 with calculated market capitalization near $12.65 billion. FY2025 revenue was $6.164 billion, trading profit was $1.211 billion, and free cash flow was $840 million. The SNN AI stock forecast uses scenario ranges rather than a guaranteed price target because China VBP, wound reimbursement changes, tariffs, US knee recovery, and multiple expansion all matter. This page is informational research and not investment advice.
Current price
$29.95 close on July 8, 2026
Market cap
$12.65 billion calculated ($29.95 x 422.52 million shares), about $12.8 billion reported reference
AI score
71 / 100
Rating
Improving mid-cap MedTech franchise after 12-Point Plan completion, with moderate valuation and execution risk still ahead
Trend status
Consolidating near the 50-day average after a pullback from the 52-week high, still above the 52-week low area
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Smith & Nephew sells orthopaedic implants, sports medicine and ENT devices, and advanced wound-care products used to repair, regenerate, and replace soft and hard tissue. | High |
| Moat | Moat comes from surgeon training, hospital relationships, clinical evidence, CORI robotics workflow, REGENETEN and other procedure brands, regulatory know-how, and global distribution scale. The moat is solid but not monopoly-like versus larger MedTech peers. | Medium-high |
| Management | CEO Deepak Nath completed the 12-Point Plan, expanded trading margin and free cash flow, launched RISE, completed Integrity Orthopaedics, and returned cash through dividends and buybacks. The next test is 2026 growth and ROIC delivery. | Medium-high |
| Financial trend | FY2025 revenue rose 6.1% reported and 5.3% underlying to $6.164 billion. Trading profit rose 15.5% to $1.211 billion, trading margin reached 19.7%, and free cash flow rose 52.5% to $840 million. Q1 2026 revenue was $1.501 billion with 3.1% underlying growth. | High |
| Valuation | At $29.95, financial_rigor.py calculates about 20.8x TTM ADS EPS of $1.442, about 2.4x book value near $12.45, about 15.1x FCF per ADR near $1.99, and a dividend yield near 2.6% on $0.782 per ADS full-year distribution context. | High for math, medium for forward value |
| Technical trend | Price is consolidating after a drawdown from the $38.79 52-week high and sits near Investing.com 50-day context around $29.84, still above the $28.56 52-week low area. | Medium |
| Risk level | Risk is medium because procedure demand is durable, but China VBP, US wound reimbursement, tariffs, product mix, FX, competition, and acquisition integration can compress growth or margins. | Medium-high |
| AI confidence | High for historical financials and company guidance language. Medium for forecast ranges because MedTech multiples and reimbursement outcomes can re-rate faster than fundamentals. | High data confidence |
| Investment certainty | Medium certainty. The turnaround evidence is real, but the stock still needs proof that RISE can convert mid-single-digit growth into higher ROIC without valuation compression. | Medium |
SNN AI stock forecast
The SNN AI stock forecast is scenario-based around the $29.95 closing price and FY2025 adjusted EPSA context of 102.0 cents per ordinary share, or about $2.04 per ADS. Using financial_rigor.py three-scenario math with EPSA-linked growth and PE assumptions produced three-year values near $51.6 in a bull case, $36.0 in a base case, and $21.6 in a bear case. These are not price promises. They show how sensitive SNN can be to organic growth, trading-margin durability, free cash flow, buybacks, and the earnings multiple investors assign to a mid-cap MedTech recovery story.
$48 to $55
More likely if underlying revenue growth holds near or above about 6%, trading profit approaches the guided $1.3 billion area, free cash flow stays near $800 million or better, US knee and CORI adoption improve, China headwinds fade, and investors re-rate SNN toward a higher-teens earnings multiple.
$34 to $38
More likely if Smith & Nephew delivers mid-single-digit organic growth, absorbs 2026 tariff and reimbursement headwinds through cost savings, keeps free cash flow constructive, and trades around a mid-teens multiple on adjusted earnings.
$20 to $24
More likely if China tendering, skin-substitute reimbursement, US knee share, or tariffs cut growth and margin expansion, free cash flow fades, or investors compress SNN toward a low-teens or lower MedTech multiple.
SNN AI technical analysis
SNN AI technical analysis is neutral to cautious as of the July 8, 2026 data cutoff. Macrotrends and Yahoo Finance showed a July 8 close of $29.95. Google Finance and related quote snapshots placed the 52-week range near $28.56 to $38.79. Investing.com showed a 50-day moving average near $29.84. The chart should be rechecked with live data before any trade because the stock has already given back a large part of the 2025 rebound.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $29.95 | July 8, 2026 closing quote used for this static page and market-cap verification. |
| Near support | $29.50 to $29.85 | The Investing.com 50-day moving-average area near $29.84 is the first near-term support zone. |
| Deeper support | $28.50 to $28.80 | This band is anchored by the reported 52-week low area near $28.56 and recent downside liquidity. |
| Near resistance | $32.00 to $33.00 | A reclaim of the early-2026 and prior consolidation zone would improve the intermediate trend picture. |
| Major resistance | $36.00 to $38.79 | The upper band includes the reported 52-week high near $38.79 and prior recovery highs from the 2025 rally. |
| Moving averages | 50-day near $29.84; longer averages higher after the 2025 rebound | Price was roughly flat versus the 50-day snapshot. Confirm the 200-day level with a live chart feed before trade decisions. |
| Momentum | Neutral after pullback | SNN has pulled back from the 52-week high and is no longer in a clean uptrend, but it has not broken the 52-week low either. |
| Volume | Often around 1.0 to 1.3 million ADR shares on typical sessions | Yahoo and Google Finance snapshots showed roughly 1 million average volume; breakouts or breakdowns need clearer sponsorship. |
| Volatility | Event-driven MedTech risk | Earnings, trading updates, China VBP news, wound reimbursement, tariffs, product launches, and FX can move the stock. |
| Invalidation | Close below $29.50, then $28.50 | A close below the 50-day area weakens the range thesis. A close below the 52-week low area would shift focus to downside risk control. |
SNN AI trading strategy
The SNN AI trading strategy is a rules-based framework, not a personalized recommendation. Use it with live charts, position sizing, earnings and trading-update dates, China and reimbursement news, tariff updates, and clear invalidation levels.
Look for SNN to hold above the $29.50 to $29.85 area, then reclaim $32 to $33 on volume above the recent average with constructive commentary on underlying growth, trading profit, free cash flow, and US Orthopaedics recovery.
A close below $29.50, or a failed reclaim of $32 with rising down-day volume, should invalidate the near-term trend setup.
If SNN pulls back toward $28.50 to $28.80 without a new thesis break, compare the selloff with Q1 and full-year growth trajectory, China headwinds, skin-substitute reimbursement, tariff cost assumptions, free cash flow, and buyback capacity.
Do not treat franchise quality as a substitute for a stop or position limit because mid-cap MedTech multiples can compress quickly when growth slows.
Track underlying revenue growth by Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management; trading margin; free cash flow; adjusted ROIC; CORI and REGENETEN adoption; China VBP; wound reimbursement; tariffs; Integrity Orthopaedics integration; and capital returns.
Reduce confidence if growth is only FX-driven, if trading profit guidance depends on temporary cost cuts, or if free cash flow quality deteriorates after working-capital benefits reverse.
Investment research summary
Customers pay Smith & Nephew for implants, sports-medicine tools, ENT devices, and wound-care products that help surgeons and care teams repair or regenerate tissue and restore patient mobility and healing outcomes.
The moat is built from clinical evidence, surgeon training, procedure workflows, CORI robotics, differentiated brands such as REGENETEN, regulatory experience, manufacturing quality, and global hospital relationships. Competitors can still erode share with better robotics, pricing, or channel intensity.
The thesis fails if China VBP deepens, US wound reimbursement cuts volumes, US knee remains sub-market, tariffs erase leverage, CORI or sports-medicine growth stalls, or the market stops paying for a mid-cap turnaround multiple after 2025 gains.
Deepak Nath has delivered the 12-Point Plan finish line: higher growth quality, 160 bps of trading-margin expansion in 2025, a large free-cash-flow step-up, portfolio rationalisation, and a second $500 million buyback announced with Q1 2026. The RISE agenda and 2028 targets are the next scorecard.
Smith & Nephew sits inside durable healthcare trends: aging populations, orthopaedic procedures, ambulatory surgery, sports repair, wound prevention, and procedure-enabling technology. These trends are long duration, but tendering and reimbursement can still interrupt local growth.
Around $30, SNN is no longer priced as a broken MedTech name. Margin of safety improves if price holds key support while underlying growth, trading profit near $1.3 billion, free cash flow near $800 million, and ROIC progress remain intact. Margin of safety shrinks if the market only pays for perfect execution.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| SNN price | $29.95 close on July 8, 2026 | Yahoo Finance and Macrotrends quote snapshots | July 8, 2026 |
| Market capitalization | About $12.65 billion calculated as $29.95 x 422.52 million shares; reported references clustered near $12.8 billion | StockTitan shares context and financial_rigor.py verification | July 8, 2026 |
| Shares outstanding | About 421.7 million to 422.5 million ADR-equivalent shares across quote sources | Yahoo Finance key statistics and Google Finance share count | July 8, 2026 |
| FY2025 revenue | $6.164 billion, +6.1% reported and +5.3% underlying; cross-validated against company results and Macrotrends | Smith+Nephew FY2025 results release | July 8, 2026 |
| FY2025 segment revenue | Orthopaedics $2.437 billion; Sports Medicine & ENT $1.934 billion; Advanced Wound Management $1.793 billion | Smith+Nephew FY2025 results release | July 8, 2026 |
| FY2025 trading profit and margin | Trading profit $1.211 billion (+15.5%); trading margin 19.7% (+160 bps); operating profit $794 million | Smith+Nephew FY2025 results release | July 8, 2026 |
| FY2025 EPS and EPSA | EPS 72.1 cents per ordinary share (144.2 cents per ADS); EPSA 102.0 cents per ordinary share | Smith+Nephew FY2025 results release | July 8, 2026 |
| FY2025 free cash flow and net debt | Free cash flow $840 million; net debt including leases $2.759 billion; adjusted net debt/EBITDA 1.7x | Smith+Nephew FY2025 results release | July 8, 2026 |
| Q1 2026 revenue and guidance | Q1 revenue $1.501 billion with 3.1% underlying growth; FY2026 guidance unchanged for about 6% underlying growth, about $1.3 billion trading profit, and about $800 million free cash flow | Smith+Nephew Q1 2026 trading update | July 8, 2026 |
| Dividend context | Full-year 2025 distribution 39.1 cents per ordinary share (78.2 cents per ADS), +4.3% year over year | Smith+Nephew FY2025 results and shareholder resources | July 8, 2026 |
| Valuation math | About 20.8x TTM ADS EPS, 2.4x book, 15.1x FCF, and about 2.6% dividend yield at $29.95 via financial_rigor.py | financial_rigor.py verification using company and quote inputs | July 8, 2026 |
| Technical range context | 52-week range near $28.56 to $38.79; 50-day moving average near $29.84 | Google Finance range context and Investing.com technical snapshot | July 8, 2026 |
| Net income cross-check | About $0.625 billion net income for 2025 on Macrotrends, consistent with EPS times share-count math near $0.63 billion | Macrotrends net income series | July 8, 2026 |
This SNN AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a promise of future performance. Forecast ranges are scenarios based on available data as of July 8, 2026 and can be wrong if earnings, rates, procedure demand, China tendering, reimbursement, tariffs, regulation, litigation, acquisitions, FX, or market multiples change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
